These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38959528)

  • 1. ZNF623 contributes to breast carcinoma progress by recruiting CtBP1 to regulate NF-κB pathway.
    Zhang Z; Fang P; Zhu J; Sun G
    Biochem Biophys Res Commun; 2024 Oct; 728():150314. PubMed ID: 38959528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of PIMREG promotes breast cancer aggressiveness via constitutive activation of NF-κB signaling.
    Jiang L; Ren L; Zhang X; Chen H; Chen X; Lin C; Wang L; Hou N; Pan J; Zhou Z; Huang H; Huang D; Yang J; Liang Y; Li J
    EBioMedicine; 2019 May; 43():188-200. PubMed ID: 30979686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of lncRNA lnc-SLC4A1-1 induced by H3K27 acetylation promotes the development of breast cancer via activating CXCL8 and NF-kB pathway.
    Yi T; Zhou X; Sang K; Huang X; Zhou J; Ge L
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3765-3773. PubMed ID: 31556319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CtBP1 promotes tumour-associated macrophage infiltration and progression in non-small-cell lung cancer.
    Wang Z; Zhao Y; Xu H; Liang F; Zou Q; Wang C; Jiang J; Lin F
    J Cell Mol Med; 2020 Oct; 24(19):11445-11456. PubMed ID: 32910558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CtBP1 transactivates RAD51 and confers cisplatin resistance to breast cancer cells.
    Deng Y; Guo W; Xu N; Li F; Li J
    Mol Carcinog; 2020 May; 59(5):512-519. PubMed ID: 32124501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CircRNF10-DHX15 interaction suppressed breast cancer progression by antagonizing DHX15-NF-κB p65 positive feedback loop.
    Zheng W; Wang X; Yu Y; Ji C; Fang L
    Cell Mol Biol Lett; 2023 Apr; 28(1):34. PubMed ID: 37101128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer.
    Raza U; Saatci Ö; Uhlmann S; Ansari SA; Eyüpoğlu E; Yurdusev E; Mutlu M; Ersan PG; Altundağ MK; Zhang JD; Doğan HT; Güler G; Şahin Ö
    Oncotarget; 2016 Aug; 7(31):49859-49877. PubMed ID: 27409664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma.
    Deng R; Huang JH; Wang Y; Zhou LH; Wang ZF; Hu BX; Chen YH; Yang D; Mai J; Li ZL; Zhang HL; Huang Y; Peng XD; Feng GK; Zhu XF; Tang J
    Mol Cancer; 2020 Aug; 19(1):122. PubMed ID: 32771023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silence of TPPP3 suppresses cell proliferation, invasion and migration via inactivating NF-κB/COX2 signal pathway in breast cancer cell.
    Ren Q; Hou Y; Li X; Fan X
    Cell Biochem Funct; 2020 Aug; 38(6):773-781. PubMed ID: 32515139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling.
    Kawabata H; Azuma K; Ikeda K; Sugitani I; Kinowaki K; Fujii T; Osaki A; Saeki T; Horie-Inoue K; Inoue S
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance.
    Birts CN; Harding R; Soosaipillai G; Halder T; Azim-Araghi A; Darley M; Cutress RI; Bateman AC; Blaydes JP
    Biol Cell; 2010 Jan; 103(1):1-19. PubMed ID: 20964627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golgi tethering factor golgin-97 suppresses breast cancer cell invasiveness by modulating NF-κB activity.
    Hsu RM; Zhong CY; Wang CL; Liao WC; Yang C; Lin SY; Lin JW; Cheng HY; Li PY; Yu CJ
    Cell Commun Signal; 2018 Apr; 16(1):19. PubMed ID: 29703230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional down-regulation of Brca1 and E-cadherin by CtBP1 in breast cancer.
    Deng Y; Deng H; Liu J; Han G; Malkoski S; Liu B; Zhao R; Wang XJ; Zhang Q
    Mol Carcinog; 2012 Jun; 51(6):500-7. PubMed ID: 21681822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RelB sustains endocrine resistant malignancy: an insight of noncanonical NF-κB pathway into breast Cancer progression.
    Wang M; Zhang Y; Xu Z; Qian P; Sun W; Wang X; Jian Z; Xia T; Xu Y; Tang J
    Cell Commun Signal; 2020 Aug; 18(1):128. PubMed ID: 32807176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-promoting properties of enolase-phosphatase 1 in breast cancer via activating the NF-κB signaling pathway.
    Bu Y; Hao J; He J; Li X; Liu Y; Ma L
    Mol Biol Rep; 2023 Feb; 50(2):993-1004. PubMed ID: 36378417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A negative feedback loop between miR-200b and the nuclear factor-κB pathway via IKBKB/IKK-β in breast cancer cells.
    Wu H; Wang G; Wang Z; An S; Ye P; Luo S
    FEBS J; 2016 Jun; 283(12):2259-71. PubMed ID: 26433127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of long chain non-coding RNA CTBP1-AS in regulation of invasion and migration of breast cancer cells.
    Cui HB; Geng CZ
    J Biol Regul Homeost Agents; 2019 May-Jun,; 33(3):773-785. PubMed ID: 31165609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LINC01426 contributes to clear cell renal cell carcinoma progression by modulating CTBP1/miR-423-5p/FOXM1 axis via interacting with IGF2BP1.
    Jiang Y; Zhang H; Li W; Yan Y; Yao X; Gu W
    J Cell Physiol; 2021 Jan; 236(1):427-439. PubMed ID: 32583425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer metastasis suppressor 1 (BRMS1) attenuates TGF-β1-induced breast cancer cell aggressiveness through downregulating HIF-1α expression.
    Cho KH; Yu SL; Cho DY; Park CG; Lee HY
    BMC Cancer; 2015 Oct; 15():829. PubMed ID: 26520789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RBM8A, a new target of TEAD4, promotes breast cancer progression by regulating IGF1R and IRS-2.
    Li F; Wang X; Zhang J; Zhang J; Jing X; Jiang Q; Zhou J; Cao L; Peng H; Tong D; Huang C
    J Transl Med; 2024 Sep; 22(1):823. PubMed ID: 39232805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.